Enzon Pharmaceuticals, Inc. (ENZN)
USD 0.15
(3.45%)
USD 0.15
(3.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.21 Million USD | 225.78% |
| 2022 | - USD | -120.04% |
| 2021 | - USD | 64.06% |
| 2020 | - USD | -34.12% |
| 2019 | -973 Thousand USD | -116.62% |
| 2018 | 5.85 Million USD | -16.45% |
| 2017 | 7 Million USD | 3.79% |
| 2016 | - USD | -65.92% |
| 2015 | 15.3 Million USD | -31.18% |
| 2014 | 28.79 Million USD | 21.47% |
| 2013 | 20.47 Million USD | 70.05% |
| 2012 | 2.61 Million USD | 514.94% |
| 2011 | -9.29 Million USD | -124.97% |
| 2010 | 8.98 Million USD | 316.44% |
| 2009 | -40.85 Million USD | -84.0% |
| 2008 | 30.39 Million USD | -16.27% |
| 2007 | 116.91 Million USD | 40.53% |
| 2006 | 17.16 Million USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 39.69 Million USD | 252.36% |
| 2003 | 43.88 Million USD | -45.64% |
| 2002 | 16.83 Million USD | 999.74% |
| 2001 | 34.73 Million USD | 133.04% |
| 2000 | 2.87 Million USD | -60.63% |
| 1999 | -8.71 Million USD | -91.49% |
| 1998 | -5.2 Million USD | 20.34% |
| 1997 | -2.8 Million USD | 46.36% |
| 1996 | -3.5 Million USD | -13.79% |
| 1995 | -4.8 Million USD | 59.44% |
| 1994 | -4.8 Million USD | 38.89% |
| 1993 | -14 Million USD | 23.28% |
| 1992 | -22.7 Million USD | -103.33% |
| 1991 | -28.4 Million USD | -115.15% |
| 1990 | -13.2 Million USD | -24.53% |
| 1989 | -10.6 Million USD | -41.33% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -325 Thousand USD | 0.31% |
| 2024 Q1 | -326 Thousand USD | -876.19% |
| 2024 Q3 | 205 Thousand USD | -8.0% |
| 2023 Q2 | -318 Thousand USD | -11.58% |
| 2023 Q1 | -285 Thousand USD | -35.07% |
| 2023 Q4 | -216 Thousand USD | 4.0% |
| 2023 Q3 | -225 Thousand USD | 29.25% |
| 2023 FY | - USD | -1.16% |
| 2022 Q2 | -303 Thousand USD | -2.02% |
| 2022 Q1 | -297 Thousand USD | -28.57% |
| 2022 FY | - USD | -120.04% |
| 2022 Q4 | -211 Thousand USD | 4.52% |
| 2022 Q3 | -221 Thousand USD | 27.06% |
| 2021 Q2 | -21 Thousand USD | -290.91% |
| 2021 Q1 | 11 Thousand USD | 102.61% |
| 2021 FY | - USD | 64.06% |
| 2021 Q3 | -228 Thousand USD | -985.71% |
| 2021 Q4 | -231 Thousand USD | -1.32% |
| 2020 Q3 | -407 Thousand USD | -72.46% |
| 2020 Q4 | -422 Thousand USD | -3.69% |
| 2020 FY | - USD | -34.12% |
| 2020 Q1 | -240 Thousand USD | 6.98% |
| 2020 Q2 | -236 Thousand USD | 1.67% |
| 2019 Q4 | -258 Thousand USD | 20.62% |
| 2019 Q3 | -325 Thousand USD | -1447.62% |
| 2019 FY | - USD | -116.62% |
| 2019 Q2 | -21 Thousand USD | 94.31% |
| 2019 Q1 | -369 Thousand USD | -105.36% |
| 2018 FY | - USD | -16.45% |
| 2018 Q1 | -311 Thousand USD | 7.72% |
| 2018 Q3 | -519 Thousand USD | -151.94% |
| 2018 Q2 | -206 Thousand USD | 33.76% |
| 2018 Q4 | 6.88 Million USD | 1426.78% |
| 2017 Q2 | 6.43 Million USD | 490.1% |
| 2017 Q3 | -184 Thousand USD | -102.86% |
| 2017 Q4 | -337 Thousand USD | -83.15% |
| 2017 FY | - USD | 3.79% |
| 2017 Q1 | 1.09 Million USD | 54.31% |
| 2016 Q4 | 707 Thousand USD | -56.09% |
| 2016 FY | - USD | -65.92% |
| 2016 Q2 | 1.83 Million USD | -27.86% |
| 2016 Q3 | 1.61 Million USD | -12.31% |
| 2016 Q1 | 2.54 Million USD | 11.62% |
| 2015 Q4 | 2.28 Million USD | -72.12% |
| 2015 Q2 | 4.67 Million USD | -0.04% |
| 2015 FY | - USD | -31.18% |
| 2015 Q3 | 8.17 Million USD | 74.89% |
| 2015 Q1 | 4.67 Million USD | -19.34% |
| 2014 Q4 | 5.8 Million USD | -23.61% |
| 2014 Q1 | 8.46 Million USD | 29.33% |
| 2014 Q2 | 6.93 Million USD | -18.15% |
| 2014 Q3 | 7.59 Million USD | 9.57% |
| 2014 FY | - USD | 21.47% |
| 2013 Q1 | 6.16 Million USD | 53.9% |
| 2013 Q4 | 6.54 Million USD | 9.57% |
| 2013 Q3 | 5.97 Million USD | 7.74% |
| 2013 Q2 | 5.54 Million USD | -10.0% |
| 2013 FY | - USD | 70.05% |
| 2012 FY | - USD | 514.94% |
| 2012 Q4 | 4 Million USD | -36.1% |
| 2012 Q3 | 6.26 Million USD | 218.56% |
| 2012 Q2 | 1.96 Million USD | 385.68% |
| 2012 Q1 | 405 Thousand USD | -5.81% |
| 2011 Q4 | 430 Thousand USD | 115.93% |
| 2011 Q3 | -2.7 Million USD | 28.19% |
| 2011 Q2 | -3.76 Million USD | -223.0% |
| 2011 Q1 | 3.05 Million USD | 148.53% |
| 2011 FY | - USD | -124.97% |
| 2010 Q1 | 33.72 Million USD | 672.78% |
| 2010 FY | - USD | 316.44% |
| 2010 Q2 | -2.69 Million USD | -107.99% |
| 2010 Q3 | -5.46 Million USD | -102.78% |
| 2010 Q4 | -6.29 Million USD | -15.22% |
| 2009 Q4 | 4.36 Million USD | -30.55% |
| 2009 Q3 | 6.28 Million USD | 148.09% |
| 2009 Q2 | 2.53 Million USD | -75.64% |
| 2009 Q1 | 10.39 Million USD | 144.34% |
| 2009 FY | - USD | -84.0% |
| 2008 Q4 | 4.25 Million USD | 8.19% |
| 2008 Q3 | 3.93 Million USD | -30.27% |
| 2008 Q1 | 6.36 Million USD | 17.04% |
| 2008 Q2 | 5.64 Million USD | -11.3% |
| 2008 FY | - USD | -16.27% |
| 2007 Q4 | 5.43 Million USD | -61.94% |
| 2007 Q2 | 1.42 Million USD | -49.75% |
| 2007 FY | - USD | 40.53% |
| 2007 Q3 | 14.28 Million USD | 904.93% |
| 2007 Q1 | 2.82 Million USD | 424.31% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | -872 Thousand USD | -106.67% |
| 2006 Q3 | 13.06 Million USD | 139.22% |
| 2006 Q2 | 5.46 Million USD | 1209.96% |
| 2006 Q1 | -492 Thousand USD | 0.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q4 | - USD | -100.0% |
| 2005 Q3 | 29.54 Million USD | 68.19% |
| 2005 Q2 | 17.56 Million USD | 100.31% |
| 2005 Q1 | 8.76 Million USD | -29.61% |
| 2004 Q1 | 12.1 Million USD | -3.9% |
| 2004 FY | - USD | 252.36% |
| 2004 Q3 | 10.69 Million USD | -52.94% |
| 2004 Q4 | 12.45 Million USD | 16.46% |
| 2004 Q2 | 22.72 Million USD | 87.7% |
| 2003 Q3 | 14.41 Million USD | 157.83% |
| 2003 Q2 | -4.49 Million USD | -240.75% |
| 2003 Q1 | 16.56 Million USD | 1.26% |
| 2003 Q4 | 12.7 Million USD | -10.68% |
| 2003 FY | - USD | -45.64% |
| 2002 Q1 | 11.03 Million USD | -13.91% |
| 2002 Q2 | 14.17 Million USD | 81.39% |
| 2002 Q4 | -10.12 Million USD | 15.05% |
| 2002 Q3 | 14.87 Million USD | 4.94% |
| 2002 FY | - USD | 999.74% |
| 2001 Q4 | 9.07 Million USD | 189.57% |
| 2001 FY | - USD | 133.04% |
| 2001 Q1 | 2.61 Million USD | 1982.38% |
| 2001 Q2 | 1.73 Million USD | -33.45% |
| 2001 Q3 | 3.13 Million USD | 80.01% |
| 2000 Q4 | 125.63 Thousand USD | 108.85% |
| 2000 Q1 | -2 Million USD | -17.82% |
| 2000 Q2 | -2.88 Million USD | -44.18% |
| 2000 Q3 | -1.4 Million USD | 50.84% |
| 2000 FY | - USD | -60.63% |
| 1999 Q2 | -1.7 Million USD | -6.25% |
| 1999 FY | - USD | -91.49% |
| 1999 Q3 | -2.1 Million USD | -23.53% |
| 1999 Q4 | -1.7 Million USD | 19.05% |
| 1999 Q1 | -1.65 Million USD | -77.78% |
| 1998 Q3 | -1.1 Million USD | 47.62% |
| 1998 FY | - USD | 20.34% |
| 1998 Q2 | -2.1 Million USD | -31.25% |
| 1998 Q4 | -900 Thousand USD | 18.18% |
| 1998 Q1 | -1.6 Million USD | -900.0% |
| 1997 Q1 | -1.6 Million USD | -222.71% |
| 1997 Q2 | -900 Thousand USD | 43.21% |
| 1997 FY | - USD | 46.36% |
| 1997 Q4 | - USD | -77.78% |
| 1997 Q3 | 900 Thousand USD | 197.83% |
| 1996 Q2 | -500 Thousand USD | 68.42% |
| 1996 Q1 | -1.7 Million USD | 20.83% |
| 1996 Q4 | -500 Thousand USD | -23.04% |
| 1996 FY | - USD | -13.79% |
| 1996 Q3 | -400 Thousand USD | 32.0% |
| 1995 FY | - USD | 59.44% |
| 1995 Q3 | -1.6 Million USD | -1700.0% |
| 1995 Q2 | 100 Thousand USD | 125.0% |
| 1995 Q1 | -200 Thousand USD | 85.71% |
| 1995 Q4 | -1 Million USD | -50.0% |
| 1994 Q1 | 1.3 Million USD | 124.07% |
| 1994 Q2 | -4.6 Million USD | -461.54% |
| 1994 Q3 | -1.6 Million USD | 51.06% |
| 1994 Q4 | -2.8 Million USD | -21.74% |
| 1994 FY | - USD | 38.89% |
| 1993 Q4 | -5.3 Million USD | 0.0% |
| 1993 Q1 | -6.5 Million USD | -19.3% |
| 1993 Q2 | -5.6 Million USD | 16.18% |
| 1993 FY | - USD | 23.28% |
| 1993 Q3 | -5.3 Million USD | 5.26% |
| 1992 Q4 | -5.6 Million USD | -9.62% |
| 1992 Q1 | -5.7 Million USD | 51.56% |
| 1992 FY | - USD | -103.33% |
| 1992 Q2 | -7.1 Million USD | -19.35% |
| 1992 Q3 | -4.9 Million USD | 29.73% |
| 1991 Q3 | -3.1 Million USD | 9.3% |
| 1991 FY | - USD | -10.29% |
| 1991 Q1 | -3.5 Million USD | -575.0% |
| 1991 Q2 | -3.7 Million USD | -13.16% |
| 1991 Q4 | -12.3 Million USD | -228.21% |
| 1990 Q2 | -12.9 Million USD | -2250.0% |
| 1990 Q3 | 100 Thousand USD | 100.78% |
| 1990 Q4 | 800 Thousand USD | 700.0% |
| 1990 Q1 | 600 Thousand USD | 0.0% |
| 1990 FY | - USD | -30.77% |
| 1989 Q3 | 600 Thousand USD | 105.83% |
| 1989 Q4 | 600 Thousand USD | 0.0% |
| 1989 Q2 | -10.3 Million USD | -2160.0% |
| 1989 Q1 | 500 Thousand USD | -37.5% |
| 1989 FY | - USD | -100.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 101.713% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 120.527% |
| SQZ Biotechnologies Company | -64.14 Million USD | 101.897% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 107.006% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 98.706% |
| Mesoblast Limited | -62.38 Million USD | 101.951% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 179.229% |
| Genus plc | 73.7 Million USD | 98.349% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 118.407% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 134.311% |
| Marizyme, Inc. | -34.28 Million USD | 103.55% |
| ContraFect Corporation | -64.99 Million USD | 101.872% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 113.874% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 126.888% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 186.816% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 146.021% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 152.371% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 334.921% |
| Accustem Sciences Inc. | -3.74 Million USD | 132.484% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 102.523% |
| EV Biologics, Inc. | -1.26 Million USD | 196.044% |
| Q BioMed Inc. | -617.62 Thousand USD | 297.044% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 65.929% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 292.44% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 153.272% |
| Biomind Labs Inc. | -1.03 Million USD | 217.636% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 87.678% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 116.994% |
| Skye Bioscience, Inc. | -13.54 Million USD | 108.983% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 181.82% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 4968.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 131.331% |
| IMV Inc. | -35.52 Million USD | 103.426% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 107.669% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 148.642% |
| GB Sciences, Inc. | -1.41 Million USD | 185.711% |
| Alpha Cognition Inc. | -9.7 Million USD | 112.539% |
| HST Global, Inc. | -5303.00 USD | 23049.274% |
| CSL Limited | 4.78 Billion USD | 99.975% |
| Halberd Corporation | -74.27 Thousand USD | 1738.417% |
| Enzolytics Inc. | -2.12 Million USD | 157.351% |
| Resverlogix Corp. | -11.74 Million USD | 110.365% |
| Affymax, Inc. | -14.29 Million USD | 108.513% |
| SYBLEU INC | -141.57 Thousand USD | 959.639% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 139.732% |
| argenx SE | -216.02 Million USD | 100.563% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 102.199% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 181.193% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -221.24% |
| AVAX Technologies, Inc. | -6.11 Million USD | 119.91% |
| Zenith Capital Corp. | -8.6 Million USD | 114.141% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.489% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 7085.822% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 149.745% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 791.382% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 103.07% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 142.077% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 216.313% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -17999.346% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 169.543% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 163.355% |
| BioStem Technologies, Inc. | -7.55 Million USD | 116.111% |
| ONE Bio Corp. | 13.61 Million USD | 91.06% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 772.049% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 159.164% |
| Agentix Corp. | -1.37 Million USD | 188.718% |
| LadRx Corporation | 412.28 Thousand USD | -195.186% |
| Cell Source, Inc. | -4.27 Million USD | 128.484% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 431.408% |
| Regen BioPharma, Inc. | 1.46 Million USD | 16.983% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 229.89% |
| NovAccess Global Inc. | -1.03 Million USD | 217.608% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 86.254% |
| Itoco Inc. | -1.86 Million USD | 165.115% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 420.584% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 209.05% |
| Kadimastem Ltd | -2.62 Million USD | 146.373% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 608.886% |
| CytoDyn Inc. | -18.02 Million USD | 106.75% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 1639.941% |
| Mobile Lads Corp. | -2.24 Million USD | 154.302% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 10051.754% |
| Qrons Inc. | -40.08 Thousand USD | 3136.351% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 350.578% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -130.74% |
| Rebus Holdings, Inc. | -951 Thousand USD | 227.971% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 214.594% |
| International Stem Cell Corporation | 202 Thousand USD | -502.475% |
| Bioxytran, Inc. | -3.82 Million USD | 131.857% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 2411.93% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 149.433% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 103.393% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 2804.444% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 144.449% |
| Neutra Corp. | -181.24 Thousand USD | 771.459% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 106.037% |
| PureTech Health plc | -11.62 Million USD | 110.467% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 106.037% |
| IXICO plc | -707 Thousand USD | 272.136% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 115.836% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 102.517% |
| CSL Limited | 4.73 Billion USD | 99.974% |
| Cellectis S.A. | -92.63 Million USD | 101.314% |